'Climb of Hope' Reaches Summit for Lymphoma
Taking the fight against lymphoma to 29,000 feet and the top of the world, South African climber Robby Kojetin, along with his climbing companion and countryman John Black, reached the summit of Nepal's towering Mount Everest recently—a climb Kojetin achieved under the auspices of his "Climb of Hope", raising money and awareness for lymphoma and for South Africa's volunteer organization Childhood Cancer Foundation.
The organization, also known as CHOC ('Childrens Haematology Oncology Clinics') was established in 1979, has eight offices located across the country, and provides children diagnosed with cancer and their families all types of support, assistance, and advocacy.
Kojetin's 'Climb of Hope' shouldn't be confused with Climb for Hope, a mountain-climbing team that raises money and awareness for breast cancer.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
